Vir Biotechnology (VIR) Retained Earnings (2018 - 2026)
Vir Biotechnology recorded quarterly Retained Earnings of -$1.3 billion in Q1 2026, down 10.49% quarter-over-quarter from -$1.2 billion in Q4 2025, and down 66910.94% year-over-year from N/an in Q1 2025.
Vir Biotechnology's Retained Earnings history runs 9 years deep, the most recent figure standing at -$1.3 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 66910.94% year-over-year to -$1.3 billion; the TTM figure through Mar 2026 stood at -$1.3 billion (down 66910.94% YoY), while the FY2025 annual figure was -$1.2 billion, down 57.65% from the prior year.
- Retained Earnings came in at -$1.3 billion for Q1 2026 at Vir Biotechnology, down from -$1.2 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $478.8 million in Q3 2022 to a low of -$1.3 billion in Q1 2026.
- A 5-year average of -$230.1 million and a median of -$2.9 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings soared 36733.51% in 2022 and slumped 93125.03% in 2024, its largest moves.
- Vir Biotechnology's Retained Earnings stood at $377.2 million in 2022, then sank by 100.22% to -$815000.0 in 2023, then plunged by 93125.03% to -$759.8 million in 2024, then tumbled by 57.65% to -$1.2 billion in 2025, then declined by 10.49% to -$1.3 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.3 billion, -$1.2 billion, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -1.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.32 Bn |
| Dec 31, 2025 | -1.20 Bn |
| Sep 30, 2025 | -1.91 Mn |
| Jun 30, 2025 | -991.71 Mn |
| Mar 31, 2025 | -1.98 Mn |
| Dec 31, 2024 | -759.78 Mn |
| Sep 30, 2024 | -655.20 Mn |
| Jun 30, 2024 | -2.88 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Dec 31, 2023 | -815,000.00 |
| Sep 30, 2023 | -121.85 Mn |
| Jun 30, 2023 | -2.90 Mn |
| Mar 31, 2023 | -3.22 Mn |
| Dec 31, 2022 | 377.24 Mn |
| Sep 30, 2022 | 478.80 Mn |
| Jun 30, 2022 | 303.50 Mn |
| Mar 31, 2022 | -4.81 Mn |
| Dec 31, 2021 | -1.10 Mn |
| Sep 30, 2021 | -1.31 Mn |
| Jun 30, 2021 | 774.30 Mn |
| Mar 31, 2021 | -836.10 Mn |
| Dec 31, 2020 | -1.28 Mn |
| Sep 30, 2020 | -561.54 Mn |
| Jun 30, 2020 | -295,000.00 |
| Mar 31, 2020 | 248,000.00 |
| Dec 31, 2019 | -601,000.00 |
| Sep 30, 2019 | 81,000.00 |
| Dec 31, 2018 | -14,000.00 |